NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RecruitingPhase 4

Sponsor: Eli Lilly and Company

Conditions: Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

Interventions: Pirtobrutinib, Idelalisib

Countries: United States, Australia, Austria, Belgium, Canada, China, Croatia, Czechia

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria:

* This is not applicable to this study

Locations (50)

Mobile, Alabama, United States
Tucson, Arizona, United States
Jacksonville, Florida, United States
Coon Rapids, Minnesota, United States
Ithaca, New York, United States
New York, New York, United States
Cincinnati, Ohio, United States
Fort Worth, Texas, United States
Kyle, Texas, United States
Melbourne, Australia
Salzburg, Austria
Roeselare, Belgium
Toronto, Canada
Beijing, China
Changsha, China
Guangdong, China
Guangzhou, China
Lanzhou, China
Nanchang, China
Shanghai, China
Taizhou, China
Tianjin, China
Tianjin, China
Ürümqi, China
Xuzhou, China
Zhengzhou, China
Zagreb, Croatia
Hradec Králové, Czechia
Rouen, France
Budapest, Hungary
+ 20 more on CT.gov